NCT06597396View on ClinicalTrials.gov

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

January 11, 2026

Study Completion Date

June 26, 2026

Conditions
Post-COVID ConditionFatigue Symptom
Interventions
DRUG

Abrocitinib

50 mg tablets

DRUG

Placebo

Tablets

Trial Locations (1)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT06597396 - Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID | Biotech Hunter | Biotech Hunter